



Gen2Co: 2nd generation *E.coli* protein cell factories


Lloyd W. Ruddock

University of Oulu, Finland

30 years ago FDA approved first recombinant biologic



In the early years prokaryotic production dominated the market



- Low cost
- Rapid growth
- High biomass
- Easy cultivation and manipulation
- FDA friendly

In the early years prokaryotic production dominated the market



But investment in eukaryotic systems has changed the balance

Current rule of thumb:

Intracellular proteins

Prokaryotic production



Extracellular proteins

Eukaryotic production

In reality the issue is post translational modifications.

In particular disulfide bond formation and N-glycosylation

Gen2Co:

Combining advantages of prokaryotic and eukaryotic organisms for recombinant protein production.

i.e. a prokaryote that can make disulfide bonded, N-glycosylated proteins in high yields and secrete them to the media.


Eukaryotic N-glycan heterogeneity

Eukaryotic proteins are often heterogenous in the number and types of N-glycans added, even on a single protein & often with significant batch-to-batch variation.

This has major implications since N-glycans can modulate:

- Biological activity
- Stability
- Clearance
- Immunogenicity

Periplasmic disulfide bond formation in *E. coli*




In vivo N-glycosylation

+

Ex vivo transglycosylation

A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylation


Flavio Schwarz¹, Wei Huang^{2,3}, Cishan Li^{2,3}, Benjamin L Schulz¹, Christian Lizak¹, Alessandro Palumbo⁴, Shin Numao¹, Dario Neri⁴, Markus Aebi^{1*} & Lai-Xi Wang^{2,3*}



Engineered pathways based on PglB promiscuity

An engineered eukaryotic protein glycosylation pathway in *Escherichia coli*


Juan D Valderrama-Rincon^{1,6}, Adam C Fisher^{2,6}, Judith H Merritt², Yao-Yun Fan³, Craig A Reading², Krishan Chhiba⁴, Christian Heiss⁵, Parastoo Azadi⁵, Markus Aebi³ & Matthew P DeLisa^{1*}



Limitations of the periplasm:


- Low volume / low capacity => low yields (?)

E.coli: Ronald Wetzel (SKB)



- Secretion machinery easily overloaded

Disulphide bond formation in the ER



Disulphide bonds are annoying


Can we use information from natural systems for disulfide bond formation in the cytoplasm of *E.coli*?

Cytoplasmic expression

Naturally reducing environment => inclusion bodies



Pathways for disulfide bond reduction in *E.coli* cytoplasm




These strains remove reducing pathways.

They do **not** add a pathway for catalyzing *de novo* disulfide bond formation

So how about adding core eukaryotic catalysts to
the cytoplasm of *E.coli*?


CyDisCo has been successfully used for >90 proteins

24 DWP screening



Total

Soluble




In excess of 250mg/L of disulfide linked Fab, from shake-flasks

CyDisCo works in **any** *E.coli* strains and in **any** media

What about adapting other systems?


How about inverting DsbB to get disulphide bond formation in the cytoplasm?



Three routes for efficient disulfide bond formation in *E.coli* cytoplasm, what about N-glycosylation?

Cytoplasmic N-glycosylation in *E.coli*

Uses N-glycosylation system from
Actinobacillus pleuropneumoniae



THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 286, NO. 40, pp. 35267–35274, October 7, 2011
© 2011 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.

Cytoplasmic N-Glycosyltransferase of *Actinobacillus pleuropneumoniae* Is an Inverting Enzyme and Recognizes the NX(S/T) Consensus Sequence^{*[5]}

Received for publication, June 28, 2011, and in revised form, August 11, 2011. Published, JBC Papers in Press, August 18, 2011, DOI 10.1074/jbc.M111.277160

Flavio Schwarz[‡], Yao-Yun Fan⁺¹, Mario Schubert^{§2}, and Markus Aebi^{‡3}


From the Institutes of [‡]Microbiology and [§]Molecular Biology and Biophysics, Department of Biology, ETH Zürich, 8093 Zürich, Switzerland

Combining CyDisCo


Combining CyDisCo with:

- Large scale production and processing

Human interleukin 6: 1.0 g/L purified product



Human growth hormone 1: 1.1 g/L purified product




scFv: 0.6g/L purified product

Combining CyDisCo with:

- N-glycosylation in the cytoplasm

In the ER disulfide bond formation goes hand in hand with N-glycosylation, can we do the same in the *E.coli* cytoplasm?






Anti N-glycosylation WB

Combining CyDisCo with:

- TAT secretion system

Twin arginine translocation system is a secretion system with in-built quality control mechanism i.e. only correctly folded proteins are secreted. Analogous to the ER-exit site quality control system.






Summary

Efficient disulfide bond formation +/- N-glycosylation in the cytoplasm of *E.coli* offers up new, interesting, possibilities for the industrial production of **homogenous** proteins in high yields.

It will not replace eukaryotic protein production, but offers an alternative solution that may create an interesting balance between eukaryotic and prokaryotic expression of biologics.

Acknowledgements



Markus Aebi (Zurich)
Robert Freedman (Warwick)
Sohvi Hörkkö (Oulu)
Eli Keshavarz-Moore (London)
Collin Robinson (Kent)

Funding:

Academy of Finland
Biocenter Oulu
Sigrid Juselius Foundation
University of Oulu